Ir para o conteúdo
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Idioma
Palavra solta
Título
Autor
Assunto
Área/Cota
ISBN/ISSN
Tag
Pesquisar
Avançada
CAPECITABINE (CAPE) +/- BEVACI...
Citar
Enviar por SMS
Enviar por email
Imprimir
Exportar registo
Exportar para RefWorks
Exportar para EndNoteWeb
Exportar para EndNote
Permanent link
CAPECITABINE (CAPE) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL
Detalhes bibliográficos
Main Authors:
Midgley, R
,
Love, S
,
Potter, V
,
Segelov, E
,
Ferry, DR
,
Weaver, A
,
Scudder, C
,
Julier, P
,
Grumett, S
,
Kerr, D
Formato:
Conference item
Publicado em:
2012
Exemplares
Descrição
Registos relacionados
Registo fonte
Registos relacionados
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Por: Kerr, R, et al.
Publicado em: (2016)
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Por: Love, S, et al.
Publicado em: (2016)
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
Por: Teschendorf Christian, et al.
Publicado em: (2011-08-01)
Capecitabine: have we got the dose right?
Por: Midgley, R, et al.
Publicado em: (2009)
Capecitabine: Have we got the dose right?
Por: Midgley, R, et al.
Publicado em: (2009)